Project Grant R01AR084284
Award Date
5/1/25
Completion Date
3/31/30
Dollars Obligated
$386K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
This federal Project Grant award, valued at $221,100.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop and evaluate in vivo gene editing strategies to repair collagen mutations in mouse models of Osteogenesis Imperfecta (OI). The research will explore the use of bone-targeting recombinant adeno-associated virus (rAAV) to deliver gene editing...
This federal Project Grant award of $159,594 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the cellular and extracellular mechanisms responsible for the skeletal defects and bone fragility caused by loss-of-function mutations in the TMEM38B gene, which encodes the TRIC-B potassium channel and affects calcium flux in osteoblasts. The research will be...
This federal Project Grant award, totaling $395,537, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant supports the development and validation of CRISPR-based genome editing strategies to correct CLCN7 gene mutations associated with osteopetrosis, a rare genetic bone disorder. The primary awardee, Brigham & Women's Hospital Inc., will work with a...
This Project Grant award of $600,475 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a collagen-based scaffold modified with specific integrin ligands and placental mesenchymal stem cell-derived extracellular vesicles. This scaffold is intended to synergistically recruit and guide endogenous stem cells for vascularized bone regeneration in utero to...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $626,879 to the University of Southern California to conduct research into the cellular and molecular mechanisms underlying large-scale bone regeneration. The research aims to unravel the intricate processes governing the initiation and coordination of extensive bone repair,...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will develop a novel gene therapy for bone healing based on adeno-associated virus (AAV) delivery of bone morphogenetic protein-2 (BMP-2). The $454,050 award, spanning February 1, 2025 to January 31, 2030, will use a validated rat model to evaluate the efficacy and quality of bone...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $378,250.00 to The Children's Hospital of Philadelphia to conduct research focused on understanding the mechanisms underlying growth plate dysfunction and developing therapeutic interventions to counter growth plate defects. The key objectives of this 6-year project are to: 1)...
This $306,872 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop an allogeneic cell-based gene therapy product for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA), a rare inherited metabolic disorder. The key objectives of this Phase I award are to: 1) produce, optimize, and analyze the characteristics of genetically-modified...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $522,334 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Connecticut Health Center. The grant will fund the development of a data repository called "BoneBase" to collect and share bone phenotyping data from rodent animal models. The project aims to build a computational infrastructure to ingest, curate, and provide access...